Inicia sesión Registrate Mi Biblioteca biblioteca abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por la International Parkinson & Movement Disorder Society.

Tratamiento farmacologico

347 ARTíCULOS , VIENDO DEL 31 AL 45

PUBMED

Small-molecule inhibitors/modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010 - 2012)

Belluti F, Rampa A, Gobbi S, Bisi A.

Expert Opin Ther Pat. 2013 May;23(5):581-96. doi: 10.1517/13543776.2013.772983. Epub 2013 Feb 21.

0

0

0

PUBMED

Neuropeptides in Alzheimer's disease: from pathophysiological mechanisms to therapeutic opportunities

Van Dam D, Van Dijck A, Janssen L, De Deyn PP.

Curr Alzheimer Res. 2013 Jun;10(5):449-68. doi: 10.2174/1567205011310050001.

0

0

0

PUBMED

Liver X receptors: emerging therapeutic targets for Alzheimer's disease

Sodhi RK, Singh N.

Pharmacol Res. 2013 Jun;72:45-51. doi: 10.1016/j.phrs.2013.03.008. Epub 2013 Mar 28.

0

0

0

PUBMED

Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study

Holthoff V, Ferris S, Gauthier S, Ihl R, Robert P, Winblad B, Sternberg K, Tennigkeit F; ROSA Study Group.

Int J Geriatr Psychiatry. 2013 Feb;28(2):164-72. doi: 10.1002/gps.3805. Epub 2012 Apr 11.

0

0

0

PUBMED

Effects of pharmacological agents, sleep deprivation, hypoxia and transcranial magnetic stimulation on electroencephalographic rhythms in rodents: towards translational challenge models for drug discovery in Alzheimer's disease

Babiloni C, Infarinato F, Aujard F, Bastlund JF, Bentivoglio M, Bertini G, Del Percio C, Fabene PF, Forloni G, Herrero Ezquerro MT, Noè FM, Pifferi F, Ros-Bernal F, Christensen DZ, Dix S, Richardson J

Clin Neurophysiol. 2013 Mar;124(3):437-51. doi: 10.1016/j.clinph.2012.07.023. Epub 2012 Oct 4.

0

0

0

PUBMED

Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications

Sabbagh JJ, Kinney JW, Cummings JL.

Neurobiol Aging. 2013 Jan;34(1):169-83. doi: 10.1016/j.neurobiolaging.2012.02.027. Epub 2012 Apr 1.

0

0

0

PUBMED

Prolonged running, not fluoxetine treatment, increases neurogenesis, but does not alter neuropathology, in the 3xTg mouse model of Alzheimer's disease

Marlatt MW, Potter MC, Bayer TA, van Praag H, Lucassen PJ.

Curr Top Behav Neurosci. 2013;15:313-40. doi: 10.1007/7854_2012_237.

0

0

0

PUBMED

[New risk genes for Alzheimer's disease--biomarkers predicting the disease?]

Hiltunen M, Haapasalo A, Soininen H.

Duodecim. 2013;129(6):583-8.

0

0

0

PUBMED

Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study

Miyoshi I, Fujimoto Y, Yamada M, Abe S, Zhao Q, Cronenberger C, Togo K, Ishibashi T, Bednar MM, Kupiec JW, Binneman B.

Int J Clin Pharmacol Ther. 2013 Dec;51(12):911-23. doi: 10.5414/CP201816.

0

0

0

PUBMED

Memantine-associated hyperkalaemia in a patient with Alzheimer's disease

Tsukamoto T, Yamada H, Uchimura N.

Psychogeriatrics. 2013 Sep;13(3):180-1. doi: 10.1111/psyg.12022.

0

0

0

PUBMED

Diffusion tensor imaging to determine effects of antidementive treatment on cerebral structural connectivity in Alzheimer's disease

Kilimann I, Likitjaroen Y, Hampel H, Teipel S.

Curr Pharm Des. 2013;19(36):6416-25. doi: 10.2174/1381612811319360003.

0

0

0

PUBMED

Missing data analysis in drug-naïve Alzheimer's disease with behavioral and psychological symptoms

Kwak YT, Yang Y, Park SG.

Yonsei Med J. 2013 Jul;54(4):825-31. doi: 10.3349/ymj.2013.54.4.825.

0

0

0

PUBMED

Adverse drug reactions in patients with Alzheimer's disease and related dementia in France: a national multicentre cross-sectional study

Laroche ML, Perault-Pochat MC, Ingrand I, Merle L, Kreft-Jais C, Castot-Villepelet A, Durrieu G, Gras V, Guy C, Jean-Pastor MJ, Jonville-Béra AP, Merlet-Chicoine I, Miremont-Salamé G, Nourhashemi F, C

Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):952-60. doi: 10.1002/pds.3471. Epub 2013 Jun 24.

0

0

0

PUBMED

Mens sana in corpore sano revisited

Jeger RV.

Eur Heart J. 2013 Sep;34(33):2580-1. doi: 10.1093/eurheartj/eht244. Epub 2013 Jul 4.

0

0

0

PUBMED

Nature as a source of metabolites with cholinesterase-inhibitory activity: an approach to Alzheimer's disease treatment

Pinho BR, Ferreres F, Valentão P, Andrade PB.

J Pharm Pharmacol. 2013 Dec;65(12):1681-700. doi: 10.1111/jphp.12081. Epub 2013 May 16.

0

0

0

Comentarios

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neuroacademy